Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,090 across all filing types
Latest filing 2018-09-10 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about the progress and specifics of using idle raised funds for cash management, including details of financial products purchased, redemption, risk control measures, approvals, and impact on operations. It is not a full financial report like an Annual Report or Interim Report, nor is it a simple announcement of a report publication. It is a regulatory announcement about capital management activities related to fundraising proceeds. This fits best under Capital/Financing Update (CAP) as it concerns updates on the company's use of raised funds and cash management activities.
2018-09-10 Chinese
关于公司获得医疗器械注册证的进展公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate from the National Medical Products Administration. It details the product information, registration certificate number, validity period, and the impact on the company. The document is short (1211 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed filing. There is no financial data, no mention of annual or quarterly results, no management discussion, no voting results, or other report types. It is a regulatory announcement about a product certification. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2018-08-27 Chinese
关于公司获得医疗器械注册证的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1095 characters) from a company about obtaining a medical device registration certificate for a specific product. It includes product details, impact on the company, and risk warnings. There is no financial data, no detailed report, no management discussion, or earnings information. The document is an official company announcement about a regulatory approval event, not a financial report or detailed filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a voting result, board change, or capital update. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2018-08-24 Chinese
关于持股5%以上股东减持股份比例达到1%的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a shareholder holding more than 5% of the company's shares reducing their stake by more than 1%. It details the shareholder's name, the number of shares reduced, the method of reduction, and compliance with relevant securities laws and regulations. There is no financial report, earnings data, or management discussion. The document is a formal notification of a major shareholding change, specifically a reduction in shareholding by a significant shareholder. This fits the definition of 'Major Shareholding Notification' (MRQ). The document length is short and focused solely on this shareholding change, confirming it is not a full report or other type of filing.
2018-08-22 Chinese
中信证券股份有限公司关于公司2018年半年度跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2018 年半年度跟踪报告' which translates to '2018 Half-Year Tracking Report' for Xiamen Aide Biomedical Technology Co., Ltd. It is prepared by CITIC Securities Co., Ltd. The content includes detailed oversight and supervision activities by the sponsor institution, compliance with regulatory requirements, review of company disclosures, governance and internal control assessments, and updates on regulatory actions and company commitments. The document contains substantive financial and operational oversight information for a half-year period (2018 first half). It is not a full annual report but a comprehensive interim report covering half-year activities and compliance. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length (13,431 characters) and detailed content confirm it is a full report, not just an announcement or certification. Hence, the classification is IR with high confidence. H1 2018
2018-08-03 Chinese
关于持股5%以上股东股份减持计划的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the shareholder's identity, the number and percentage of shares to be reduced, the methods and timing of the reduction, and related commitments and risk warnings. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is an announcement about a planned shareholding reduction by a significant shareholder, which fits the definition of a Major Shareholding Notification (MRQ). The document length is 2037 characters, which is consistent with an announcement rather than a full report.
2018-08-02 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.